Relmada Therapeutics, Inc. (RLMD): Price and Financial Metrics


Relmada Therapeutics, Inc. (RLMD): $22.21

1.58 (+7.66%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add RLMD to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

RLMD Stock Price Chart Interactive Chart >

Price chart for RLMD

RLMD Price/Volume Stats

Current price $22.21 52-week high $39.66
Prev. close $20.63 52-week low $16.23
Day low $20.81 Volume 355,800
Day high $22.41 Avg. volume 286,656
50-day MA $24.30 Dividend yield N/A
200-day MA $22.73 Market Cap 666.10M

Relmada Therapeutics, Inc. (RLMD) Company Bio


Relmada Therapeutics, Inc. is a clinical stage, public specialty pharmaceutical company who develops a variety of established drug products. The Company also researches and procures chemical entities with a focus on the treatment of pain.


RLMD Latest News Stream


Event/Time News Detail
Loading, please wait...

RLMD Latest Social Stream


Loading social stream, please wait...

View Full RLMD Social Stream

Latest RLMD News From Around the Web

Below are the latest news stories about Relmada Therapeutics Inc that investors may wish to consider to help them evaluate RLMD as an investment opportunity.

Relmada posts topline data for lead asset in abuse potential trial against ketamine

The development stage biotech company, Relmada Therapeutics (NASDAQ:RLMD) announced on Wednesday the topline results from the human abuse potential (HAP) study for its lead candidate REL-1017, currently in Phase 3 development for major depressive disorder (MDD). The Phase 1 study was designed to assess the abuse potential of REL-1017 vs....

Seeking Alpha | February 23, 2022

Relmada Aces REL-1017 Vs Ketamine Study For Abuse Potential

Relmada Therapeutics Inc (NASDAQ: RLMD) has announced topline results of the human abuse potential (HAP) study with REL-1017 for major depressive disorder or MDD. REL-1017 is a novel NMDA receptor (NMDAR) channel blocker and the Company's lead candidate. The results showed that all three doses of REL-1017 (25 mg, 75 mg, and 150 mg) tested in recreational drug users demonstrated a substantial (30+ points) and statistically significant difference vs. intravenous ketamine 0.5 mg/kg over 40 minutes

Yahoo | February 23, 2022

Relmada Therapeutics Announces Top-Line Results of Study Evaluating REL-1017 vs Ketamine for Abuse Potential

Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced top-line results of the human abuse potential (HAP) study with REL-1017, a novel NMDA receptor (NMDAR) channel blocker and the company's lead candidate in Phase 3 development for the treatment major depressive disorder (MDD).

Yahoo | February 23, 2022

Relmada Therapeutics to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer, and Maged Shenouda, Chief Financial Officer, will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17, 2022 at 8:00am Eastern Time.

Yahoo | February 10, 2022

Wall Street Analysts See a 231% Upside in Relmada Therapeutics, Inc. (RLMD): Can the Stock Really Move This High?

The mean of analysts' price targets for Relmada Therapeutics, Inc. (RLMD) points to a 231.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Yahoo | January 12, 2022

Read More 'RLMD' Stories Here

RLMD Price Returns

1-mo N/A
3-mo 14.78%
6-mo 5.46%
1-year -36.45%
3-year 161.91%
5-year 455.25%
YTD -1.42%
2021 -29.75%
2020 -17.77%
2019 747.83%
2018 53.33%
2017 -31.19%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7224 seconds.